Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  Central Coast Health Watch  >  Current Article
Premium Content

Atara Biotherapeutics angles for $92M, but jobs are scarce

By   /   Friday, August 29th, 2014  /   Comments Off on Atara Biotherapeutics angles for $92M, but jobs are scarce

Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.

    Print       Email
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email